RATIONALE: The serotonergic agonist, meta-chlorophenylpiperazine (mCPP), produces inconsistent effects on obsessive-compulsive disorder (OCD) symptoms, perhaps because clinical studies have not utilized a homogenous OCD subgroup of patients. OBJECTIVES: This study aimed to evaluate mCPP effects on functional components of compulsive checking, using the quinpirole sensitization rat model of OCD. METHODS: In study 1, the effects of mCPP were evaluated in quinpirole rats with compulsive checking. Two experimental groups were co-injected with quinpirole (0.125 mg/kg) and mCPP (0.625 or 1.25 mg/kg), while one control group was co-injected with quinpirole (0.125 mg/kg) and saline and the other control group received co-injections of saline. In study 2, mCPP (0, 0.3125, 0.625, and 1.25 mg/kg) was administered repeatedly to naïve rats and induction of compulsive checking evaluated. RESULTS: mCPP significantly attenuated quinpirole-induced compulsive checking behavior by reducing vigor of checking (indexed by frequency of checking and length of check) and increasing rest after a bout of checking (indexed by time to the next checking bout), but it did not affect focus on the task of checking (indexed by recurrence time of checking and number of stops before returning to check). In naïve rats, mCPP did not induce compulsive behavior, but the highest dose reduced vigor of checking performance compared to saline controls. CONCLUSIONS: mCPP did not exacerbate or induce compulsive checking behavior. Instead, it ameliorated compulsive checking by reducing vigor of checking and increasing post-checking satiety, without affecting focus on checking. Ameliorative effects of mCPP may involve 5HT2A/2C receptors in substantia nigra pars reticulata that inhibit expression of motor vigor.
RATIONALE: The serotonergic agonist, meta-chlorophenylpiperazine (mCPP), produces inconsistent effects on obsessive-compulsive disorder (OCD) symptoms, perhaps because clinical studies have not utilized a homogenous OCD subgroup of patients. OBJECTIVES: This study aimed to evaluate mCPP effects on functional components of compulsive checking, using the quinpirole sensitization rat model of OCD. METHODS: In study 1, the effects of mCPP were evaluated in quinpirolerats with compulsive checking. Two experimental groups were co-injected with quinpirole (0.125 mg/kg) and mCPP (0.625 or 1.25 mg/kg), while one control group was co-injected with quinpirole (0.125 mg/kg) and saline and the other control group received co-injections of saline. In study 2, mCPP (0, 0.3125, 0.625, and 1.25 mg/kg) was administered repeatedly to naïve rats and induction of compulsive checking evaluated. RESULTS:mCPP significantly attenuated quinpirole-induced compulsive checking behavior by reducing vigor of checking (indexed by frequency of checking and length of check) and increasing rest after a bout of checking (indexed by time to the next checking bout), but it did not affect focus on the task of checking (indexed by recurrence time of checking and number of stops before returning to check). In naïve rats, mCPP did not induce compulsive behavior, but the highest dose reduced vigor of checking performance compared to saline controls. CONCLUSIONS:mCPP did not exacerbate or induce compulsive checking behavior. Instead, it ameliorated compulsive checking by reducing vigor of checking and increasing post-checking satiety, without affecting focus on checking. Ameliorative effects of mCPP may involve 5HT2A/2C receptors in substantia nigra pars reticulata that inhibit expression of motor vigor.
Authors: E Hollander; C DeCaria; R Gully; A Nitescu; R F Suckow; J M Gorman; D F Klein; M R Liebowitz Journal: Psychiatry Res Date: 1991-01 Impact factor: 3.222
Authors: W K Goodman; C J McDougle; L H Price; L C Barr; O F Hills; J F Caplik; D S Charney; G R Heninger Journal: Biol Psychiatry Date: 1995-08-01 Impact factor: 13.382
Authors: T A Pigott; J L Hill; T A Grady; F L'Heureux; S Bernstein; C S Rubenstein; D L Murphy Journal: Biol Psychiatry Date: 1993-01-01 Impact factor: 13.382
Authors: Mark C Tucci; Anna Dvorkin-Gheva; Renee Sharma; Leena Taji; Paul Cheon; John Peel; Ashley Kirk; Henry Szechtman Journal: Psychopharmacology (Berl) Date: 2014-02-28 Impact factor: 4.530
Authors: Henry Szechtman; Susanne E Ahmari; Richard J Beninger; David Eilam; Brian H Harvey; Henriette Edemann-Callesen; Christine Winter Journal: Neurosci Biobehav Rev Date: 2016-05-07 Impact factor: 8.989
Authors: Javier Ballester González; Anna Dvorkin-Gheva; Charmaine Silva; Jane A Foster; Henry Szechtman Journal: Behav Pharmacol Date: 2015-02 Impact factor: 2.293
Authors: Dawn M Eagle; Cristie Noschang; Laure-Sophie Camilla d'Angelo; Christie A Noble; Jacob O Day; Marie Louise Dongelmans; David E Theobald; Adam C Mar; Gonzalo P Urcelay; Sharon Morein-Zamir; Trevor W Robbins Journal: Behav Brain Res Date: 2014-01-06 Impact factor: 3.332
Authors: Mark C Tucci; Anna Dvorkin-Gheva; Eric Johnson; Paul Cheon; Leena Taji; Arnav Agarwal; Jane Foster; Henry Szechtman Journal: Eur J Neurosci Date: 2014-06-16 Impact factor: 3.386